Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03052725 · ClinicalTrials.gov registry record · Phase 3
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Terminated
- Registry status
- Phase 3
- Development phase
- 391
- Enrollment target
NCT03052725 is a Phase 3 study that was terminated before completion, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 391 participants.
The verdict
NCT03052725, a Phase 3 study, was terminated before completion, sponsored by Teva Branded Pharmaceutical Products R&D.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 391 participants
- Enrollment target
Study Summary
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.
Interventions
- DRUG reslizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2017-03-10 |
| Est. Completion | 2018-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03052725
The ClinicalTrials.gov registry entry for NCT03052725 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 391 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which reslizumab is the first listed.
NCT03052725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03052725 about?
NCT03052725 is a clinical study titled "A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma". This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment peri...
What is the current status of trial NCT03052725?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 391 participants. The study started on 2017-03-10. Estimated completion is 2018-02-22.
What interventions are being tested in trial NCT03052725?
The interventions under investigation include: reslizumab (DRUG).
Who is sponsoring clinical trial NCT03052725?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.